Accelerating Multi-Site Assay Screening: 4x Throughput for Emerging Biopharma
How a clinical-stage oncology biopharma unified 4 international CRO pipelines into an automated, GxP-validated screening lakehouse, cutting cycle times from 14 days to under 48 hours.
Client Challenge & Operational Bottleneck
Our client, a Series B precision oncology biopharma running simultaneous Phase 1/2 trials, partnered with four external contract research organizations (CROs) across Europe and North America. Each CRO delivered plate-reader assays, cellular toxicity screens, and pharmacokinetic measurements in disparate formats: CSV files, bespoke instrument exports, and password-protected spreadsheets.
The internal computational chemistry team spent more than 40 hours per screening run manually reconciling batch IDs, normalizing concentration response curves, and resolving compound nomenclature discrepancies. By the time compound potency trends were identified, lead candidate validation was delayed by an average of two weeks.
The Architectural Solution
Husk Labs engineered an automated, multi-tenant scientific data pipeline that directly integrated each CRO's data drops into a centralized AWS & Databricks lakehouse:
1. Zero-Trust Secure SFTP & API Ingestion: Built automated listeners that ingest raw analytical files with end-to-end cryptographic checksums the moment CROs upload deliverables. 2. Automated Schema & Quality Validation: Implemented an automated validation engine that verifies compound SMILES, batch IDs, and control calibration standards prior to ingestion. 3. Real-Time Curve Fitting Engine: Replaced manual Excel curve fitting with an automated R/Python non-linear regression pipeline executing automatically inside the lakehouse. 4. Interactive Scientist Portal: Deployed a role-based dashboard allowing discovery biologists to view real-time IC50/EC50 curves and hit selection metrics within minutes of data landing.
Measurable Scientific Outcomes
The modernized architecture delivered dramatic operational and scientific acceleration across the entire discovery pipeline:
- Cycle Time Reduction: Reduced raw data-to-decision time from 14 calendar days down to under 48 hours.
- 4.2x Screening Throughput: Scaled weekly compound screening capacity by over 400% without adding headcount.
- 100% Audit Provenance: Provided full 21 CFR Part 11 compliant audit logs for every mathematical transformation, ready for regulatory filing.
- Elimination of Data Errors: Reduced transcription and manual unit conversion errors to zero.